MC4R Inhibitors
1 drugsAbout MC4R
The melanocortin 4 receptor (MC4R) is a G protein-coupled receptor crucial in regulating energy homeostasis. It plays a key role in energy balance, making it a compelling drug target, especially in the metabolic therapeutic area.
Currently, there is no genetic evidence available linking MC4R to specific diseases. However, its established function in energy balance supports pharmacological intervention for metabolic disorders.
One FDA-approved drug, IMCIVREE, targets MC4R, highlighting the therapeutic potential of this receptor. IMCIVREE, a small molecule, is marketed by RHYTHM for 5 indications in the metabolic therapeutic area.
Top MC4R Drugs
RHYTHM is the only company with an approved drug targeting MC4R.
The market is highly concentrated, suggesting high barriers to entry or limited commercial opportunity.
MC4R Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets MC4R, using small molecule modality.
Explore opportunities to develop novel biologics targeting MC4R to diversify the therapeutic landscape.
MC4R Clinical Trials 22 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on MC4R. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 9 | 7 | 0 | 2 | 100% |
| Phase 3 | 9 | 7 | 0 | 2 | 100% |
| Phase 4 | 2 | 1 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
MC4R Drug Approval Timeline (2020 - 2020)
The first and only drug targeting MC4R, IMCIVREE, was approved in 2020.
Recent approval suggests a growing interest in MC4R, but market saturation is low, indicating potential for new entrants.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 3 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on MC4R. A trial counts if an approved drug acting on MC4R is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.